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In 1994, we pioneered a complementary DNA (cDNA) sequencing project that aimed to predict the
primary structures of unknown human proteins. Although our cDNA project was focused on the
sequencing of large cDNAs, the following cDNA sequencing projects conducted by other groups have
more extensively characterized mammalian transcriptome. In parallel, many groups have made a
tremendous amount of effort to develop various resources for functional human genomics. In this
context, to demonstrate the power of functional genomic approaches in practice, we have applied
them for a comprehensive understanding of the immune system, which we term ‘immunogenom-
ics’. This mini-review ﬁrst describes the historical background of our cDNA project and then pro-
vides perspectives on the present and future of immunogenomics based on our experiences.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Historical background: dawn of mammalian transcriptomic
and proteomic analyses
In 1994, at Kazusa DNA Research Institute (KDRI), we initiated
the analysis of the complete sequence of randomly sampled human
complementary DNA (cDNAs) [1]. In this project, we intended to
determine entire sequences of cDNAs and thereby to discover
uncharacterized human protein-coding sequences encoded by
the human genome; at that time, human cDNA analysis was
mainly focused on the collection of expressed sequence tags [2].
The unique feature of our cDNA project is that the sequencing ef-
forts have been focused on long cDNAs (>4 kb) that encode large
proteins (>1000 amino acid residues) [3]. The novel human genes
thus identiﬁed by our cDNA project were systematically desig-
nated as ‘KIAA’ plus a four-digit number; the number of ‘KIAA’
genes has today reached 2038 [4]. Subsequently, following our
example, other research groups initiated highly comprehensive ef-chemical Societies. Published by E
te; PID, primary immunode-
o-dimensional electrophore-
eﬁciency Diseases; RefDIC,
ORF, protein-coding region;
n the genome
arch, Kazusa DNA Research
-0818, Japan. Fax: +81 438 52
i.riken.jpforts to completely sequence mammalian (particularly human and
mouse) cDNAs; although I cannot refer to each of the mammalian
cDNA projects because of space limitation, many novel and unex-
pected aspects of the mammalian transcriptome have been re-
vealed by their projects [5]. Together with the genomic sequence
data, the accumulated data from such comprehensive analyses of
mammalian cDNAs continue to serve as a solid basis for decipher-
ing the mammalian transcriptome and proteome.
With the availability of the draft of the human genome se-
quence in 2001, cDNA analysis for discovering new human genes
inevitably entered an end-game phase, at least for protein-coding
genes. Consequently, we decided to terminate the ﬁrst phase of
the human cDNA project and to advance beyond the identiﬁcation
of transcribed sequences. From our perspective, it was natural to
focus on the functional characterization of KIAA genes and their
products in the second phase of our cDNA project because more
than half of KIAA genes were not functionally annotated although
we expected them to have certain special functions in mammals.
Interestingly enough, large proteins encoded by large genes such
as KIAA genes are expected to play a special and crucial role in
the mammalian system [3]. This shift in focus from the transcrip-
tome to the proteome was also a trend in the research community
at that time. However, our practical concern was how to take
advantage of the accumulated cDNA information and clone re-
sources to reach our ultimate goal—a comprehensive understand-
ing of the structure and function of the biological system. Inlsevier B.V. All rights reserved.
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function at the protein level via the analysis of cDNA because the
true functional players in the biological system are proteins. In this
regard, we believed that the cDNA clones thus accumulated in our
project served as an indispensable and versatile resource for the
functional genomics research community. After considerable
deliberations, we decided to take an approach called ‘afﬁnity pro-
teomics’ [6]. In this approach, a large set of recombinant proteins
derived from genes of interest are generated using their cDNA
clones and used as antigens to raise antibodies. The raised antibod-
ies are then used for characterization of the gene products in vivo
by immunohistochemistry, protein blotting analysis, antibody ar-
ray assays, pull-down experiments of the protein complex, and
so on. We conducted such a project from 2002 to 2006, raising
approximately 2000 antibodies against mouse KIAA proteins and
analyzing these proteins in vivo by using these antibodies [7]. A
similar, but more extensive and sophisticated, afﬁnity proteomics
approach is now being arranged for human gene products through
an international collaboration of other groups [8].
The numerous completely sequenced cDNA clones are now
indispensable reagents for experimental exploration in mamma-
lian genomics. To support this impetus in research, a large number
of protein-coding regions (which are conventionally designated as
ORFs, although ORF was originally an abbreviation for open read-
ing frame) excised from whole cDNAs have been cloned into vec-
tors compatible with high-throughput cloning systems in the
‘ORFeome project’ [9,10]. The objectives of this project are exactly
those envisioned by most human cDNA sequencing projects and
are thus being realized through the means of international collab-
orations (Ref. [11], http://www.orfeomecollaboration.org/). While
ORF clones thus shared by international collaboration are based
on a recombination cloning method, it is worth noting that our
ORF clones are prepared by a restriction enzyme-based high-
throughput cloning system (Flexi Cloning System, Promega Co.,
WI, USA) and the HaloTag protein-tagging technology (Table 1;
http://www.kazusa.or.jp/kop/dsearch-e/) [12].
In this way, dramatic progress has been made in mammalian
transcriptomics and proteomics in the last decade. As an example,
the outcomes of the projects conducted by KDRI are summarized in
Table 1. In the context of the extensive functional genomics re-
sources and know-how at KDRI, we considered that it is our
responsibility to demonstrate the power of functional genomics
in real-world biology. While there are many biological ﬁelds that
could beneﬁt from fully exploiting genomic resources, we have
decided to become involved in immunological research. Therefore,
this minireview hereafter describes the aim of our functional
genomics research in immunology, termed ‘immunogenomics’,
along with a perspective of the current status and future direction
of our immunogenomics research.
2. What does immunogenomics comprise?
Genomics is a relatively new term in biology and encompasses a
broad range of biological studies. Because a genome is the sum to-Table 1
Databases generated by the Kazusa mammalian cDNA projects.
Database name URL Descr
HUGE http://www.kazusa.or.jp/huge/ Hum
ROUGE http://www.kazusa.or.jp/rouge/ Roud
NEDO http://www.kazusa.or.jp/NEDO/ Datab
InGaP http://webcreate.kazusa.or.jp/create/ Datab
InCeP http://webcreate.kazusa.or.jp/create/ Datab
KOP http://www.kazusa.or.jp/kop/ Datab
a http://www.promega.com/applications/immdet/imaging/halotag/.tal of all the genes in an individual organism, genomics has been
regarded as a high-throughput and quantitative form of biology.
The advent of genomics has spawned the neologism ‘omics’ be-
cause the characteristics of genomics are quite distinct from those
of conventional biology. According to the Omics.org portal site
(http://omics.org/), ‘omics’ takes a certain philosophical perspec-
tive, which suggests a trend toward an integrative, rather than a
reductionist, approach in biology. Interestingly, during the early
emerging phase of the use of the term ‘omics’, some researchers
emphasized the new aspects of a hypothesis-free (or data-driven)
approach in biology with some others negating it [13–16]. As
pointed out in [15], however, hypothesis-driven and data-driven
approaches are never mutually exclusive. An important point is
that genomics produces a huge amount of data which enables us
to begin our analysis using data, and not entirely using theory or
hypothesis. In this sense, ‘omics’ has just provided us with a new
gateway into complex biological events that are too complicated
for hypothesizing in advance. In this regard, it is crucial that the
genomics data are shared with the research community because
the more the data the better it is across all genomic approaches.
Without data sharing in the research community, the amounts of
data available for individual research groups would be too small
to have a data-driven approach.
Although used in a similar context as that of ‘omics’, the term
‘systems biology’ is frequently used in a more detailed and special-
ized context than the term ‘omics’. For example, the deﬁnition of
‘systems biology’ in Wikipedia (http://en.wikipedia.org/wiki/Sys-
tems_biology) is as follows: ‘A relatively new biological study ﬁeld
that focuses on the systematic study of complex interactions in
biological systems, thus using a new perspective (integration in-
stead of reduction) to study them’. Thereafter, it has been stated
that one of the goals of systems biology is to discover new emer-
gent properties that may arise from the systemic view used by this
discipline in order to better understand the entirety of processes
that happen in a biological system. The phrase ‘to better under-
stand the entirety’ is considerably popular among biologists, thus
increasing the popularity of ‘systems biology’. However, this sim-
ply reminds me of an old book entitled ‘Cybernetics’ [17], which
I was very excited about more than 30 years ago. The main differ-
ence between the era of ‘systems biology’ and the era described in
Cybernetics is that the genome information provides us with an al-
most-complete list of functional elements in the biological system,
i.e. the proteins. In this respect, a recent study by Kitano’s group
might be regarded as an orthodox systems-biological descendent
of Cybernetics [18]. To further move beyond ‘Cybernetics’ and bet-
ter understand the entirety of the biological system from the com-
plete list of proteins, we may need to devise a novel and logical
framework; this is an exciting challenge in the post-genomic era.
In this minireview, ‘immunogenomics’ is used to include
genomics focused on immunology, although the usage of this term
has been fairly recent and infrequent in literature. Because the im-
mune system in mammals is one of the most complex biological
systems, we consider it the most challenging target ﬁeld to demon-
strate the power of genomic approaches. Furthermore, we believeiption
an unidentiﬁed-gene encoded large protein database
ent unidentiﬁed-gene encoded large protein database
ase for human long cDNAs in spleen
ase for gene expression/protein proﬁles obtained by using mouse KIAA antibodies
ase for intracellular pathways based on mouse KIAA protein-protein interactions
ase for Kazusa ORF clones and expression clones for the ORF-HaloTag fusionsa
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lems might bring about a breakthrough in immunology because
it will effectively complement conventional immunological ap-
proaches. Although there are various types of important properties
of the immune system to be explored via genomic approaches, we
have hereafter focused our discussion on mRNA and/or protein
proﬁling of the immune cells because of space constraints.3. Immunogenomics resources and their application to
real-world immunology
3.1. Resources for immunogenomics
As described above, a data-driven approach can be a good alter-
native to a conventional hypothesis-driven one, particularly when
the phenomenon of interest is too complex to establish hypotheses
in advance. However, the data-driven approach cannot be realized
without high-quality genomic data. In this respect, transcriptomic
data are the most practically suited to being comprehensively tack-
led with current technology. For this purpose, DNA microarray
technology has already opened a way to accumulate large amounts
of data regarding genome-wide gene expression proﬁles. The
description of biological systems with tens of thousands of differ-
ent mRNA levels is highly sensitive to the state of those systems.
Although mRNA proﬁles obtained by DNA microarray analyses
are not absolutely quantitative and somewhat depend upon the
types of DNA microarray platforms, DNA microarray technology
has already been demonstrated to uncover intriguing features of
gene expression proﬁles in various biological events. However,
when we planned to implement a genomics basis in immunology,
there was no open-access database of mRNA proﬁles of immune
cells. Thus, we ﬁrst worked on generating a reference database of
gene expression in immune cells. It was our plan to freely provide
the research community with the resulting informational resource
of gene expression of immune cells because data sharing plays a
pivotal role in genomics. To achieve this purpose, we invited many
researchers in the RIKEN Research Centre for Allergy and Immunol-
ogy (http://www.rcai.riken.jp) to collaborate with us.
As we began to construct this immunogenomics database, we
were concerned that mRNA proﬁles alone would not be sufﬁcient
to reveal the molecular mechanisms underlying the observed bio-
logical events. This is mainly because mRNA levels are not always
directly relevant to biological phenomena; mRNA is a template for
protein synthesis and is not itself a functional element in most
cases. Protein proﬁles have a closer relevance to biological events
than do mRNA proﬁles because it is the proteins that directly gov-
ern biological events. The scarcity of quantitative proteomic data
was thus a serious concern when analyzing the immune system
from an ‘omics’ viewpoint. To address this problem practically,
we previously generated quantitative proteomic maps based on
two-dimensional gel electrophoresis (2DE) and included these
quantitative data in our immunogenomics database [19].
In order to integrate the ‘omics’ data obtained for various im-
mune cells, we annotated each sample with a controlled vocabulary
and implemented a relational database that included the quantita-
tive mRNA and protein proﬁling data as described above. Our
immunogenomics database, termed ‘Reference genomics Database
of Immune Cells’ (RefDIC), offers a web-based query interface and
user-friendly facilities for visualizing data, and allows all of the
raw data to be downloaded [20]. RefDIC could serve as a solid refer-
ence for the transcriptome and proteome of immune cells, and
hence could greatly facilitate the identiﬁcation of immunologically
important genes and proteins that are involved in various immune
responses, through cross-referencing quantitative mRNA and pro-
tein proﬁling data [20]. The number of mRNA/protein proﬁles inRefDIC continues to grow and its data-viewing functions have also
been enhanced continuously (Fig. 1).
On similar lines, several groups have also constructed their own
gene expression databases to date [21–23]. Among them, the
Immunological Genome project (the ImmGen project, http://
www.immgen.org) aims to construct an open-access database
focusing on immune cells; their data are also shared with the re-
search community, like ours [24]. Interestingly enough, on the ba-
sis of their data as well as ours, two-thirds of the genome has been
found to be active in at least one immune cell type; moreover, only
less than 1% of genes are expressed exclusively in a given type of
immune cell. This implies that most immunological phenomena
should be interpreted in the framework of the whole system rather
than as functions of a small set of genes speciﬁc to a given type of
immune cells. In other words, characteristic phenotypes of im-
mune cells are likely to result mainly from characteristics of the
whole system of the gene expression network.
3.2. Technological problems in proteome analyses in immunogenomics
Although protein proﬁle data based on 2DE have been included,
an obvious weakness of the RefDIC datasets is the low comprehen-
siveness of the proteome data. Our quantitative proﬁles in RefDIC
based on 2DE comprise the proﬁle of only several hundred proteins
that occur in abundance in immune cells. This is generally very
problematic in practice and needs to be resolved. Advances in mass
spectrometry-based proteomics have made it possible to obtain
absolute quantities of several thousand proteins [25], but these
techniques are still in their infancy from the viewpoint of compre-
hensive protein proﬁling. In addition, many functionally important
proteins in immunology are not abundant, or even very rare, in
many cases. Thus, it would be difﬁcult to comprehensively analyse
these functionally important proteins (e.g. cytokines/chemokines
and transcription factors) by even the most advanced mass spec-
trometry-based proteomic approaches. One possible solution for
this is to again take an afﬁnity proteomics approach as described
in Section 1. Although it is still impossible to comprehensively
monitor protein proﬁles in a genome-wide fashion, current anti-
body array technology enables us to monitor more than several
tens of protein levels simultaneously with very high sensitivity.
We are now collecting cytokine proﬁles in this manner and will
soon be depositing these data in RefDIC. Similarly, we will be able
to monitor the protein levels of transcription factors that are rele-
vant to immunological events. Another solution to this issue is to
monitor the levels of mRNA engaged in translation, instead of the
total mRNA present in immune cells. In practice, this can be
achieved by mRNA proﬁling analysis of polysomal RNAs. Through
this approach, we can monitor the mRNA translation proﬁles that
are expected to correlate well with the rates of protein production.
Thus, although this approach cannot monitor the levels of accumu-
lated protein in immune cells, the mRNA proﬁles thus obtained are
easier to interpret in terms of protein production. Taking this
approach, we could partially identify post-transcriptional gene reg-
ulation in a macrophage-like cell line elicited by a lipopolysaccha-
ride [26].
A technological concern intrinsic to both transcriptomic and
proteomic data is that they are obtained only as snapshots and
as averages of an immune cell population. As demonstrated re-
cently [27], bio-imaging may provide a partial answer to this
concern because quantitative bio-imaging data are obtained for
single cells, not populations, and can be followed over time. Thus,
we need a new logic and framework to deal with these new
types of data when integrating single-cell based data with conven-
tional genomic data. This raises a difﬁcult but exciting technolog-
ical challenge for the future, and will be discussed in detail in
Section 4.
Fig. 1. Snapshots of RefDIC. Panel A shows a top page of RefDIC (http://refdic.rcai.riken.jp/). Panels B and C display mRNA proﬁles in a radar chart format and a heat-map
format, respectively. Panel D is an example of comparison of protein and mRNA proﬁles (indicated by ﬁlled and open arrows, respectively) in various samples in a heat-map
format.
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diseases
While there are some technological limitations as described
above, the use of the accumulated mRNA proﬁle data has already
proven to be very powerful in practice. One of the most exciting
cases is the identiﬁcation of four genes which convert ﬁbroblasts
to induced pluripotent stem cells [28]. This is a case of success
through ‘signature’ identiﬁcation. A ‘signature’ is a set of genes
identiﬁed by comparison of mRNA proﬁles of cells under condi-
tions deﬁned from a perceived biological logic as described in
[22]. In many cases, signature analysis is very informative in
immunology and is frequently performed in a hypothesis-free
manner. In addition to signature analysis, integration of multiple
types of genomic data is also considered to be highly useful [29].
However, from my perspective, it is more intriguing to apply
immunogenomics to highly complex immune events which are be-
yond the reach of current reductive approaches. In this regard, dis-
ease studies can be a touchstone since they require highly
integrative approaches to ﬁll the gap between genotypes and phe-
notypes. It would be important to know how far we can assess the
relationship between genotypes and phenotypes via genomic ap-
proaches since disease studies are deﬁnitely multi-scale analyses
and require highly integrative knowledge of biological systems.
To achieve this, we ﬁrst need a solid basis of disease-related infor-
mation. As an example of disease studies, we have recently begunconstructing a database of primary immunodeﬁciency diseases
(PIDs). Because all the genetic causes of PIDs identiﬁed so far are
single gene mutations, the information required is more straight-
forward than in other immunological diseases. Thus, we have con-
structed a web-based compendium of molecular alterations in PID,
named the Resource of Asian Primary Immunodeﬁciency Diseases
(RAPID), which is available as a worldwide web resource at http://
rapid.rcai.riken.jp/ [30]. RAPID hosts information on manually cu-
rated sequence variations, gene expression proﬁles, immune path-
way information, and various lines of information at the protein
level of PID genes (Fig. 2). RAPID is in its early infancy, but will cer-
tainly make it easier to integrate various lines of information and
data mining for the analysis of PID. However, most of the informa-
tion currently stored in RAPID is at the molecular level. Thus, we
must obtain more information regarding the phenotypes of PIDs
in relation with genotypes in the future. Only then will we be able
to tackle the challenging issue of understanding the entirety better
by fully exploiting immunogenomics approaches.4. Future direction: to develop single-cell based genomics for a
comprehensive systematic understanding of the immune
system
As described earlier, the amounts of information accumulated
in immunogenomics have continuously increased and are already
Fig. 2. Integration of various genomic information for PID genes on RAPID. A screen shot of the top page of RAPID is shown (http://rapid.rcai.riken.jp/RAPID/) at the top of this
ﬁgure. After selecting a PID gene from the gene query section, various types of information for the PID gene are linked. Snapshots of representative linked sites are shown with
their URLs.
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mic approach is now widely accepted in general, but the limita-
tions and pitfalls of current genomics technologies, particularly
for the analysis of biological systems consisting of multiple cells
such as the immune system, have also become evident. Among
them, how to characterize multi-scale biological systems with het-
erogeneous cell populations at the molecular level is one of the
most critical problems in functional genomics. From my perspec-
tive, we will confront this difﬁcult problem most speciﬁcally in
immunology because dynamic changes in cell population and
interactions among heterogeneous cells play an essential role in
immunological events.
The limitations and pitfalls described above originate from cur-
rent technological limitations of molecular proﬁling. For example,
although cell designation by using a ﬂuorescence-activated cell
sorter has been used for many years and is believed to be robust,
our experience as well as the ﬁndings of the early conﬁrmation
studies in the ImmGen project have indicated that the mRNA pro-
ﬁle data obtained using identically designated cell populations in
different laboratories vary considerably. Because we obtained the
mRNA proﬁles as averages of cell populations, we cannot identify
whether the inter-laboratory variability originates from heteroge-
neity in the collected cells or from intrinsic differences in individ-
ual cells. Thus, how to move beyond ‘the myth of the average cell’
is closely related to an essential problem, i.e. how to experimen-
tally obtain a systems view of the immune system as discussed
in [31]. More importantly, even if a cell population is composed
of clonal cells, cell-to-cell variations do exist. It is interesting to
note that phenotypic cell-to-cell variability within clonal popula-
tions could arise from the slow ﬂuctuation of protein levels in
mammalian cells [32,33]. Therefore, not only heterogeneity of cell
types but also cell-to-cell variations of clonal cells must be taken
into consideration to understand the immune system from a sys-
tems-biological viewpoint. This will also raise a new theoretical/philosophical problem of how to deal with biological systems con-
sisting of heterogeneous cells, where a reductive approach seems
almost useless.
From a technological viewpoint, a solution to this problem has
already come from bio-imaging technology. The current imaging
technology enables us to monitor the behavior of even a single
molecule in a living cell in a quantitative manner. In addition,
in vivo imaging technology has advanced rapidly and thereby we
may soon be able to follow the behavior of single cells in vivo in
real time. Nonetheless, as discussed by Albeck et al. [34], the most
productive and reliable approach in practice is to integrate and
compare data obtained by both population-based (or bulk) and sin-
gle-cell approaches because at present, genomic data can be ob-
tained only for a population and the data from single-cell
approaches are full of noise. It would be interesting to observe
what could happen if the simultaneous measurement of a large
number of mRNA and/or protein levels in many single cells is pos-
sible. Single-cell mRNA/protein proﬁling will produce drastically
increased amounts of quantitative data and enable us to character-
ize complex cell ensembles at the molecular level. Although Mar
et al. pioneered this direction of analysis using a mesoscopic ap-
proach [35], more straightforward technologies for biochemical/
genomic analyses of single cells are right around the corner
[36,37]. Therefore, it is time to seriously consider the logic required
to deal with these data with theoreticians and/or computational
scientists. Together with the accumulated genomic data, these
new genomic data at the single-cell level will deepen our knowl-
edge of multicellular biological systems, although the research
community might be thrown into confusion at the beginning. This
situation might bear some analogy to the early phase of the emer-
gence of statistical mechanics from thermodynamics. In the next
10 years, biology may change drastically in this direction. In my
outlook, immunogenomics will surely play a pivotal role in this
process.
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